← Leaderboards
Ralph A Tripp
University Of Georgia
$7,550,886
Attributed
$10,681,198
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,681,198 · 9
By mechanism
R01$9,308,082 · 5
R21$794,566 · 2
R56$558,550 · 1
R13$20,000 · 1
Top collaborators
- Balazs Rada7 shared
- Rebecca Michelle Dubois5 shared
- Richard A. Dluhy1 shared
- Stephen Mark Tompkins1 shared
Others in their field
Top investigators on “Virus Diseases”
- Barton F Haynes · Duke University$305,832,186
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Lawrence Corey · Fred Hutchinson Cancer Center$271,990,515
- Richard Webby · St. Jude Children'S Research Hospital$264,105,723
- David Heimbrook · Leidos Biomedical Research, Inc.$262,417,885
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$252,117,999
Research focus
Virus DiseasesLungResponsePathogenesisPreventAffectVaccinationImmuneCellsLeukocytesCytokineMouse ModelRespiratory Syncytial Virus InfectionsChildRespiratory Syncytial VirusRespiratory Syncytial Virus VaccinesElderlyDesignInnovationInfantVirusImmune ResponseImmunityProteins
Grant awards (25)
Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity$754,322
R01 · FY2025 · AI
Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity$754,322
R01 · FY2024 · AI
Dual oxidase and lactoperoxidase in influenza infection$377,500
R01 · FY2024 · AI
Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity$754,322
R01 · FY2023 · AI
Dual oxidase and lactoperoxidase in influenza infection$377,500
R01 · FY2023 · AI
Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity$767,822
R01 · FY2022 · AI
Dual oxidase and lactoperoxidase in influenza infection$377,500
R01 · FY2022 · AI
Dual oxidase and lactoperoxidase in influenza infection$377,500
R01 · FY2021 · AI
Dual oxidase and lactoperoxidase in influenza infection$377,500
R01 · FY2020 · AI
Structure-guided design of a safe and effective Respiratory Syncytial Virus G protein immunogen$558,550
R56 · FY2019 · AI
The Role of Oxidative Epithelial Defenses in Influenza Infection$225,000
R21 · FY2018 · AI
The Role of Oxidative Epithelial Defenses in Influenza Infection$187,500
R21 · FY2017 · AI
KPT-335 as novel therapeutic for respiratory syncytial virus$165,933
R21 · FY2016 · AI · contact PI
KPT-335 as novel therapeutic for respiratory syncytial virus$216,133
R21 · FY2015 · AI · contact PI
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload$563,843
R01 · FY2014 · AI · contact PI
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload$528,153
R01 · FY2013 · AI · contact PI
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload$557,928
R01 · FY2012 · AI · contact PI
Determination of Markers of High Pathogenicity in Influenza$278,464
R01 · FY2012 · GM
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload$573,233
R01 · FY2011 · AI · contact PI
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload$593,052
R01 · FY2010 · AI · contact PI
Antibody inhibition of respiratory syncytial virus G protein activity$317,507
R01 · FY2010 · AI · contact PI
Antibody inhibition of respiratory syncytial virus G protein activity$320,713
R01 · FY2009 · AI · contact PI
Antibody inhibition of respiratory syncytial virus G protein activity$320,713
R01 · FY2008 · AI · contact PI
Antibody inhibition of respiratory syncytial virus G protein activity$336,188
R01 · FY2007 · AI · contact PI
Immunobiology of Influenza Virus Infection: Approaches for an Emerging Zoonotic D$20,000
R13 · FY2007 · AI · contact PI